Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Discontinuation by "tapering" vs usual family planning care

Adverse events · participants with depressive or anxiety disorders

It is very uncertain whether discontinuation by "tapering" changes adverse events compared with continuation (or usual care) (very low certainty).

1 finding from 1 review

Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety… 2021 · Cochrane Headline outcomes only
OR 1.06 [0.82, 1.38]
7 studies · 1479 participants
Very low

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.24 [0.42, 3.7]
2 studies · 317 participants
Very low

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

The review found no eligible studies for this question.

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found